Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2013-10-22 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 90% confidence The document is a press release dated October 22, 2013, announcing a positive Data and Safety Monitoring Board (DSMB) recommendation to continue a Phase III clinical trial (ReLive) for the drug Livatag®. This content focuses on clinical trial progress, safety data assessment, and future development timelines, rather than routine financial reporting (like 10-K, ER, IR) or governance matters (like DEF 14A, CGR). It is an announcement regarding ongoing operational/development activities. Since there is no specific category for 'Clinical Trial Update' or 'Press Release', and the content is highly specific operational news, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/operational announcement, or potentially 'LTR' if the DSMB review was mandated by a regulatory body, but RNS is the safer general announcement fallback.
2013-10-22 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 22, 2013, from BioAlliance Pharma announcing a positive recommendation from the independent Data Safety and Monitoring Board (DSMB) to continue its Phase III clinical trial (ReLive) for the drug Livatag®. This announcement concerns the progress of a clinical study and is a general corporate update regarding R&D activities, not a full financial report (10-K, IR), an earnings release (ER), or a specific regulatory filing like DIRS or DIV. Since it is an announcement about a specific corporate development (clinical trial progress) that doesn't fit the other specific categories (like M&A, Capital Change, or Board Change), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official company announcements not covered elsewhere, or potentially as a general corporate update. Given the options, RNS is the most appropriate fallback for a specific, non-financial, non-governance corporate news release.
2013-10-22 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 22, 2013, announcing the launch of BioAlliance Pharma's new website. It contains general company information, product pipeline updates, and forward-looking statements, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement. Since it does not fit into specific categories like AGM-R, MANG, DIRS, or DIV, and it is not an announcement about publishing another report (RPA), the most appropriate fallback category is Regulatory Filings (RNS) for miscellaneous corporate news releases that don't fit elsewhere, although it is primarily a press release announcing a website launch.
2013-10-22 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a short press release dated October 22, 2013, announcing the launch of the company's new website. It contains general company information, product pipeline updates, and standard disclaimers. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed report (IR, AR). Since it is a general announcement about company news that doesn't fit into the more specific categories (like management change, dividend, or capital change), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as per the fallback rule for miscellaneous announcements.
2013-10-22 English
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly discloses the "total number of voting rights and number of shares in the capital" as of a specific date (September 30, 2013), citing French commercial code and AMF regulations. This type of mandatory disclosure regarding the total share count and voting rights is a specific regulatory filing requirement, often related to capital structure updates or general shareholder information. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it deals directly with the number of shares and voting rights, it most closely aligns with Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the specific nature of disclosing the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, CAP is a strong candidate. However, it is a direct regulatory disclosure mandated by the AMF, which often falls under general regulatory announcements if a more specific code isn't available. Reviewing the definitions, it is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue (SHA). Because it is a formal disclosure of the current capital structure based on regulatory requirements, and it doesn't fit perfectly into SHA (which implies an *action* like an issue/buyback), RNS (Regulatory Filings) serves as the most appropriate general category for mandatory, non-periodic regulatory disclosures that don't fit elsewhere, although CAP is related. Given the context of French regulatory disclosure of share capital count, RNS is the safest fallback for mandatory regulatory updates that aren't explicitly about dividends, M&A, or insider trades.
2013-10-07 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions composant le capital au 30 septembre 2013" (Information relating to the total number of voting rights and shares comprising the capital as of September 30, 2013). It explicitly references compliance with the French Commercial Code (Code de commerce) and the General Regulation of the AMF (Autorité des Marchés Financiers). This type of periodic disclosure, detailing the total number of shares and voting rights, is a mandatory regulatory filing in France, often related to capital structure updates or pre-AGM requirements. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it is a specific regulatory disclosure about share capital and voting rights that doesn't fit perfectly into the other specific categories like DIRS (Director's Dealing) or SHA (Share Issue), it falls best under the general regulatory filing category, RNS, or potentially a specific capital/share structure notification. Given the content focuses purely on the total count of shares and voting rights as of a specific date, it is a mandatory regulatory disclosure. While SHA relates to share changes, this is a periodic count. RNS is the best fit as a general regulatory announcement that doesn't match the other specific types, although it is closely related to capital structure. However, looking closely at the definitions, it is a specific notification about the capital structure and voting rights, which is a common regulatory requirement. Since there isn't a specific code for 'Total Voting Rights Disclosure', RNS (Regulatory Filings) serves as the appropriate fallback for mandatory, non-standard disclosures. The document length is short (2488 chars), but it is the report itself, not an announcement of a report, so the RPA rule does not strictly apply here to classify it as RPA.
2013-10-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.